Sonya Heltshe, PhD

Sonya  Heltshe,  PhD


Academic Title: Associate Professor, Pediatrics

Research Title: Director of Biostatistics, Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute

Research Center: Center for Respiratory Biology and Therapeutics

"Everyday I am able to apply math and think creatively to solve problems and improve the health of others. I also love the people I work with at Seattle Children's, who have endless motivation, compassion and integrity. Every year someone with cystic fibrosis (CF) comes to talk to us about how research has touched their lives and families; I am always humbled and moved by the honesty and openness of these children and adults living with CF."

  • Biography

    I am a biostatistician working in clinical trials for Cystic Fibrosis.

    I received my PhD in Biostatistics from the University of Colorado School Of Public Health in 2007 and completed a post-doc at the National Cancer Institute in 2009. As the Director of Biostatisics at the CF Foundations Therapeutic (CFFT) Development Network and Assistant Professor of Pediatrics at the University of Washington I am the statistician and principal investigator for many CF studies of all phases, from basic research to large scale epidemiologic studies. I have interests in statistical analyses and methodologies related to CF lung function, microbial diversity, proteomics, inflammatory markers, and predictive biomarkers. I am deeply committed to evidence based medicine and ethical research in pediatric disease.

  • Patient Testimonials

  • Publications

    Manuscripts in Refereed Journals

    • Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B
      Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
      22944725 Journal of Cystic Fibrosis, 2012 Aug. : PMCID:PMC3696392

    Other Publications

    • Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, Adam RJ, Carter S, Grogan B, Launspach JL, Donnelly SC, Gallagher CG, Bruce JE, Stoltz DA, Welsh MJ, Hoffman LR, McKone EF, Singh PK
      Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
      28222269 American journal of respiratory and critical care medicine, 2017 Jun 15 : 195(12)1617-1628 PMCID:PMC5476912
    • Leung DH, Heltshe SL, Borowitz D, Gelfond D, Kloster M, Heubi JE, Stalvey M, Ramsey BW, Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.
      Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.
      28437538 JAMA pediatrics, 2017 Jun 1 : 171(6)546-554
    • Heltshe SL, Cogen J, Ramos KJ, Goss CH
      Cystic Fibrosis: The Dawn of a New Therapeutic Era.
      27710011 American journal of respiratory and critical care medicine, 2017 Apr 15 : 195(8)979-984 PMCID:PMC5422649
    • Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JL
      Pregnancy among cystic fibrosis women in the era of CFTR modulators.
      28190780 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017 Feb 9 : PMCID:PMC5550358
    • Stalvey MS, Pace J, Niknian M, Higgins MN, Tarn V, Davis J, Heltshe SL, Rowe SM
      Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.
      28143919 Pediatrics, 2017 Feb. : 139(2) PMCID:PMC5260152
    • Muhlebach MS, Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F, Pilewski J, Mayer-Hamblett N, Joseloff E, Sagel SD
      Biomarkers for cystic fibrosis drug development.
      28215711 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016 Nov. : 15(6)714-723 PMCID:PMC5321565
    • Heltshe SL | Goss CH | Thompson V | Sagel SD | Sanders DB | Marshall BC | Flume PA
      Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
      25911223 Thorax, 2015 Apr 24
    • Muhlebach MS | Heltshe SL | Popowitch EB | Miller MB | Thompson V | Kloster M | Ferkol T | Hoover WC | Schechter MS | Saiman L | the STAR-CF Study Team
      Multicenter Observational Study on Factors and Outcomes Associated with Different MRSA Types in Children with Cystic Fibrosis.
      25745825 Annals of the American Thoracic Society, 2015 Mar 6
    • Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM, GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
      Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor.
      25425629 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015 Mar 1 : 60(5)703-12
    • Rowe SM | Heltshe SL | Gonska T | Donaldson SH | Borowitz D | Gelfond D | Sagel SD | Khan U | Mayer-Hamblett N | Van Dalfsen JM | Joseloff E | Ramsey BW | GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
      Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
      24927234 American journal of respiratory and critical care medicine, 2014 Jul 15 : 190(2)175-84 PMCID:PMC4226057
    • DeBoer EM, Swiercz W, Heltshe SL, Anthony MM, Szefler P, Klein R, Strain J, Brody AS, Sagel SD
      Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis.
      Chest, 2014 Mar 1 : 145(3)593-603 PMCID:24114359


Research Description

Biostatistics, clinical trials, and translational research in Cystic Fibrosis and Pulmonology